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Abstract 
Background: Candida spp. are dimorphic fungi in the family Cryptococcaceae. Infections with Candida spp. are usu-
ally rare conditions in dogs, but immunocompromised patients have a higher risk for developing invasive candidal 
infections.
Case presentation: A 5-year-old male Boxer, positive to Leishmania infantum, was referred to the Veterinary Teach-
ing Hospital of the Department of Veterinary Medicine, University of Perugia, Italy for examination of a non-weight 
bearing left hind limb lameness of a duration of at least 3 months. During this period, treatment involved systemic 
anti-inflammatory medications and intra-articular corticosteroid administration. On presentation, clinical examination 
and radiographic findings were suggestive of cranial cruciate ligament deficiency. To support this diagnosis a stifle 
arthroscopy was performed: it confirmed a partial rupture of cranial cruciate ligament. Samples culture of synovial 
fluid and membrane was routinely collected as well, and revealed Candida guilliermondii joint infection. Treatment for 
the C. guilliermondii joint infection involved systemic anti-fungal therapy, joint lavage and intra-articular administration 
of antifungal drugs. Lameness improved markedly during this treatment, but lameness did not resolve completely, 
probably due to cranial cruciate ligament deficiency. Tibial tuberosity advancement (TTA) was chosen in order to treat 
stifle instability and was performed 4 weeks following cessation of treatment of the C. guilliermondii joint infection. Six 
month after TTA the dog showed a completely recovery with no lameness.
Conclusions: To the authors’ knowledge, this is the first case of Candida spp. joint infection reported in dogs. The 
cause of the progression of the joint C. guilliermondii infection remains unclear but it may be associated with leishma-
niasis or intra-articular corticosteroid injections. Treatment with systemic and intra-articular anti-fungal therapies was 
successful. In the evaluation of hind limb lameness in a chronically immunocompromised dog, it would be advisable 
to consider also an intra-articular Candida spp. infection.
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Background
Candida species are the most frequently cultured fungi 
in healthy dogs. They are ubiquitous organisms existing 
almost exclusively as commensal organisms, which rarely 
become pathogenic [1]. Candida spp. can be isolated in 
animals from skin and oral, gastrointestinal, upper res-
piratory, and genital mucosae. In humans, contamina-
tion resulting in infection has been reported following 
iatrogenic compromise of dermal integrity [1]. In human 
medicine Candida spp. synovitis/arthritis has been 
associated with intra-articular administration of ster-
oids in order to treat different kind of pathologies such 
as osteoarthritis and rheumatoid arthritis [2]. The most 
used intra-articular treatments are methylprednisolone 
acetate (40–80  mg), triamcinolone hexacetonide (20–
40  mg) and triamcinolone acetonide (40  mg); the dura-
tion of treatments depends on the type of disease [2]. 
Intra-articular glucocorticoids may impair local immune 
defences. The importance of aseptic technique dur-
ing intra-articular administration of glucocorticoids, in 
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order to decrease the occurrence of secondary infection, 
has been documented [2, 3]. Whilst reports of bacterial 
synovitis/arthritis in dogs are non-uncommon, reports 
on Candida-associated arthritis have apparently not been 
published yet, although fungal joint infections have been 
reported in horses [4–8]. The purpose of this case report 
is to document a successful treatment with a combina-
tion of joint lavage, systemic and local antifungal drugs of 
a solitary case of a Candida guilliermondii joint infection 
in a dog.
Case presentation
A 5-year-old Boxer with a body weight of 30  kg was 
admitted to the Veterinary Teaching Hospital of Perugia 
University, Italy for evaluation of a left hind limb lame-
ness due to a suspected left cranial cruciate deficiency. 
Lameness had been present for at least 3 months. During 
that period, treatment was carried out by other veterinar-
ians and had involved systemic anti-inflammatory medi-
cation for 2  weeks and intra-articular glucocorticoid 
administration (drugs and dosages not assessable). Clini-
cal examination revealed reluctance to walk, grade 5/5 
lameness based on the Quinn scale [9] and moderate left 
hind limb muscle atrophy presumed to be secondary to 
disuse. At rest, the dog demonstrated toe-touching or 
non-weight bearing left hind limb lameness. Examination 
revealed a moderate thickening over the medial aspect of 
the proximal tibia consistent with medial buttress [10]. 
Manipulations of the joint elicited severe resentment. 
The cranial drawer and tibial thrust tests were inconclu-
sive. Neurological examination was unremarkable. Exam-
ination of the lumbar and lumbosacral spine and hips did 
not elicit any reaction. After sedation with dexmetedomi-
dine1 (4  μg/kg intravenously [IV]), a radiographs of the 
pelvis and the left hind limb were taken and revealed 
peri-articular new bone formation in the medial part of 
the stifle consistent with moderate osteoarthritis and 
increased synovial fluid volume (effusion). Haematology 
revealed moderate anaemia (red blood count 
[RBC]4.87 × 106 cells/µl, Hematocrit [Hct] 33.8 %, com-
plete blood count [cBC] 12.4  ×  103  cells/µl) and high 
level of total proteins (9.3  g/dl), while biochemical 
parameters were within normal range. A possible expla-
nation for the elevated total proteins and anaemia was 
leishmaniasis and testing subsequently confirmed Leish-
mania infantum specific antibodies (1/160 Immunofluo-
rescence antibody test [IFAT]). Left stifle arthroscopy 
was performed. Samples of synovial fluid and synovial 
membrane and villi were collected and submitted for cul-
ture and sensitivity testing. Before premedication with 
1 Dexdomitor®: Orion Corporation Orion Pharma, Espoo, Finland.
acepromazine2 (10 μg/kg IV) and methadone3 (0.2 mg/kg 
IV), carprofen4 (4 mg/kg, IV) was administered preemp-
tively [11]. General anaesthesia was induced with propo-
fol5 (3  mg/kg IV), and maintained after endotracheal 
intubation with a mixture of isoflurane6 and oxygen (50–
100 ml/kg/min) via a circle breathing circuit with sponta-
neous ventilation. The left hind limb was prepared for 
aseptic surgery: trichotomy and aseptic disinfection were 
performed with a wide margin around the left stifle 
extending from the proximal third of the femur to the 
distal third of the tibia. Prior to arthroscopy samples of 
synovial fluid were collected by needle arthrocentesis 
after a small (8  mm) stab incision. The arthroscopic 
examination was performed using an arthroscope7 con-
nected to a video camera and image-recording device.8 
The arthroscope was introduced at the level of Gerdy’s 
tubercle, 2  mm lateral to the patellar tendon. The joint 
cavity was carefully explored and three samples of syno-
vial membrane were gathered with a 2  mm biopsy for-
ceps. Menisci were examined by visualization and 
probing as recommended [12]. A small longitudinal tear 
was identified in the cranial horn of the medial meniscus, 
more precisely in the cranial tibial ligament of the medial 
meniscus nearby the intermeniscal transverse ligament. 
In addition, the craniomedial band of cranial cruciate lig-
ament was ruptured, while the caudolateral band 
appeared grossly intact. The joint was flushed continu-
ously during joint exploration with sterile saline using a 
proximal medial parapatellar outflow cannula. At the end 
of surgery, the arthroscope and surgical instruments were 
removed and the joint was flushed copiously with lac-
tated Ringer’s solution [13]. After recovery from anaes-
thesia, to provide postoperative analgesia, 
buprenorphine9 (0.015 mg/kg subcutaneously [SC]) was 
administered three times a day [TID] for 1 day while car-
profen (see footnote 4) (2  mg/kg SC) was given once a 
day for 10 days. Laboratory findings of the synovial fluid 
are reported in Table 1.
Smears from synovial fluid were stained with May Gru-
enwald-Giemsa and examined under a light microscope. 
The sample showed a blue proteinaceous background 
and a mixed inflammatory cell population, with some 
2 Prequillan®, Fatro Spa, Bologna, Italy.
3 Eptadone®, Molteni Spa, Firenze, Italy.
4 Rimadyl®, Zoetis Inc. New Jersey, Stati Uniti.
5 Proposure®, Merial Italia Spa, Milano, Italy.
6 Isoflo; Esteve Spa, Milano, Italy.
7 2.7  mm, 30° oblique arthroscope, Small Joint Arthroscope: Karl Storz 
GmbH & Co. KG, Tuttlingen, Germany.
8 Digital Video Camera DC-1300, NeoMed®, Gutach im Breisgau, Germa-
nia; Keymat DVD + RW video recorder, Nola, Italy.
9 Temgesic®, RB Pharmaceuticals Limited, Milano, Italy.
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yeasts as shown in Fig.  1. Synovial fluid and small frag-
ments of the capsule were pre-enriched on 5 ml of triptic 
soy broth (TSB) medium and incubated at 37  °C. After 
48  h, 100  µl of each broth cultures was subcultured for 
aerobic bacteria and fungi on blood agar, MacConkey 
agar and Sabouraud dextrose agar at 37  °C in 5–10  % 
CO2. No bacterial growth was observed but a massive 
growth of yeast with the morphology of Candida spp. 
was isolated after 24 h of incubation from both synovial 
fluid and the fragments of synovial tissue. The identifica-
tion of Candida spp. was based on phenotypic feature 
such as a description of the macro- and micromorphol-
ogy and through fermentation of carbohydrates and aux-
anographic using a commercial yeast identification (Api 
20 C Aux Biomerieux10). Colonies grown on Sabouraud 
dextrose agar were subjected to polymerase chain reac-
tion (PCR) amplification and sequencing analysis in 
order to determine the Candida species. One fungal col-
ony was transferred in a 1.5 ml tube containing 200 µl of 
distillated water. DNA was extracted using the QIAamp 
DNA mini kit11 in accordance to manufacturer’s instruc-
tions and the D1/D2 region of the 26S rRNA gene was 
amplified by PCR assay, as previously described [14]. 
PCR positive reactions were purified using Wizard SV 
Gel and PCR Clean-up System (Promega, Madison, WI, 
U.S.A.) in accordance with the manufacturer’s recom-
mended protocol and subjected to direct sequencing. 
Consensus sequences were created with the BioEdit 
10 Api 20 C Aux Biomerieux, Marcy-l´Étoile, France.
11 Qiagen, Hilden, Germany.
Sequence Alignment Editor Software v 7.0.9.0 and then 
searched against the Genbank database. The isolated 
Candida sp. was thereby identified as C. guilliermondii.
Before treatment was initiated with antifungal drugs, 
sampling of synovial material was repeated with the same 
aseptic procedure and growth of C. guilliermondii was 
confirmed. Culturing of blood and urine samples did not 
produce Candida colonies and consequently systemic 
candidiasis was rejected. Antifungal therapy was started 
with fluconazole12 (5  mg/kg per oral [PO] for 10  days; 
once a day). The intra-articular treatment was performed 
under general anaesthesia: after premedication with dex-
medetomidine (see footnote 1) (4  μg/kg Intramuscular 
[IM]) and methadone (see footnote 3) (0.2  mg/kg IM), 
general anaesthesia was induced with propofol (see foot-
note 5) (3  mg/kg IV), and maintained as previous 
described. The left hind limb was then prepared for asep-
tic procedure and copious joint lavage (30 ml/kg of lac-
tated Ringer’s solution) and intra-articular administration 
of 10 ml (0.7 mg/kg) of 0.2 % fluconazole13 solution were 
performed on alternate days for three times. Synovial 
fluid analysis after 9 days of treatment, failed to culture 
C. guilliermondii. Two weeks following initiation of intra-
articular treatment, clinical examination revealed signifi-
cant improvement in function with 1/5 left hind limb 
lameness (lameness barely detectable) and no resentment 
to manipulation of the left stifle. Radiography of the stifle 
revealed a similar grade of osteoarthritis but an evident 
decrease of synovial volume. Systemic treatment for 
leishmaniasis was instituted. New samples of synovial 
fluid from the left stifle were collected during TTA 
1 month later and sent to the same diagnostic laboratory 
involved for previous testing. These samples were nega-
tive for bacterial and fungal growth (serial clinical proce-
dures and treatments carried out are listed in Table  2). 
Six month after TTA surgery the referring veterinarian 
reported that the dog showed a clinical improvement 
with no lameness (0/5).
Candida spp. are opportunistic pathogens often caus-
ing severe systemic infections in immunocompromised 
patients [15, 16]. In humans, Candida spp. induced-
arthritis is a rare disease and most of the cases have been 
also associated with immunosuppressive conditions such 
12 Diflucan®, Pfizer, New York, USA.
13 Fluconazolo ratiopharm®, Ratiopharm Italia Srl, Assago, Italia.
Table 1 Laboratory findings of the synovial fluid
WBC white blood count, RBC red blood count
Colour Appearance Quantity (ml) Protein (g/dl) WBC (cells/µl) RBC (cells/µl) Glucose (mg/dl)
Reddish Cloudy 12 3.5 35,000 250 <10
Fig. 1 Cytological appearance of the synovial fluid. 4–6 µm wide 
yeasts (arrow) and some neutrophils containing yeasts (arrowheads) 
were observed with May-Grünwald-Giemsa








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 5 of 7Bufalari et al. Acta Vet Scand  (2016) 58:47 
as cancer, AIDS, organ transplantation, chronic renal 
failure, steroid use, and heroin abuse [17–19]. Although 
virtually any joint can be affected, large, weight-bearing 
joints such as the knees are most commonly involved 
[15]. Candida guillermondii is widely distributed in 
nature, frequently isolated from the environment and it is 
a part of saprophyte human and animal microflora on the 
skin and mucosal surfaces. However, it is considered to be 
an uncommon causative agent of disease [20]. Reports of 
Candida spp. infections in dogs are rare as well. Candida 
guilliermondii was isolated from cutaneous candidiasis 
in a dog [21]. Systemic candidiasis has been reported in 
dogs causing signs of acute onset with pyrexia and septic 
shock [22, 23, 24]. Localized candidiasis is often asymp-
tomatic [17], although in chronically immunosuppressed 
dogs with involvement of the skin, nail beds, urinary 
tract, ears, and gastrointestinal tract have been described 
[1, 25]. A single report describes an intra-articular fungal 
(Blastomyces spp.) infection in the carpus of a Labrador 
retriever, which was treated successfully with itracona-
zole PO [26]. To the authors’ knowledge this is the first 
report of a C. guilliermondii joint infection in a dog. Can-
dida spp. infections have been associated with immuno-
suppression in dogs and humans [15]. Four mechanisms 
may have contributed to the development of C. guil-
liermondii infection in the present case: leishmaniasis, 
intra-articular steroids [27], repeated needle puncture 
compromising the skin barrier [4, 7], and lymphoplas-
macytic synovitis observed especially in Boxer dogs [28]. 
Although minimally invasive techniques such as joint 
puncture are not an important risk factor for develop-
ing infective arthritis, in our opinion joint injections 
pose a potential risk for microbiological joint contamina-
tion that may evolve in infection especially in attenuated 
immune response dogs. Intra-articular injections of glu-
cocorticoids are widely used in arthritic human patients 
[29, 30], despite some evidence that intra-articular ster-
oids do not influence the expression of some important 
mediators of inflammation and cartilage destruction 
[31, 32]. It has been reported that bacterial DNA is fre-
quently found in canine synovial tissue from cranial 
cruciate ligament rupture joints, possibly as a result of 
altered immune defences, which may relate to lymphop-
lasmacytic inflammation [28]. In the current case, leish-
maniasis may have contributed to destabilize the dog’s 
immune system [33] by promoting the rooting of the C. 
guilliermondii. Moreover, intra-articular glucocorticoids 
may also have induced a status of local immune suppres-
sion that may have created a favourable environment for 
C. guillermondii. In the authors’ opinion both previously 
performed intra-articular treatments and the instabil-
ity due to the cruciate deficiency, maybe have had major 
roles among the predisposing factors for developing 
joint fungal infections. In our opinion the elimination of 
C. gulliermondii was indicated prior to treatment of the 
leishmaniasis due to the possible side effects and toxic-
ity of drugs resulting from the combined treatment. The 
therapy of leishmaniasis was appropriate prior to sur-
gery to stabilize the stifle in order to reduce the com-
plications that may arise by the oxidative stress caused 
by the surgical procedure in an immunocompromised 
patient. Optimal treatment of C. guilliermondii arthritis 
has not been established [17]. Antifungal susceptibility 
testing is usually unstandardized and unreliable [34], so 
antifungal agents that are effective against a broad spec-
trum of medically important Candida spp. are recom-
mended. In one recent report, a woman with Candida 
spp. infection of a joint was treated with joint debride-
ment and antifungal medications, such as amphotericin B 
(0.5–1 mg/kg/day IV) and fluconazole (400 mg/day PO) 
[17]. Amphotericin was given IV for 3 weeks and PO flu-
conazole was prescribed for 6  months. Amphotericin B 
is a polyene antifungal commonly used for overwhelm-
ing systemic mycoses and leishmaniosis [1]. Flucona-
zole is an antifungal drug with higher affinity for fungal 
enzymes in comparison to ketoconazole or itraconazole. 
Its bioavailability is elevated after IV or PO administra-
tion [1]. A long-term survey of Candida spp. infections 
demonstrated that fluconazole had fewer side effects and 
a superior antifungal effect than amphotericin B [35]. 
Treatment of a Candida spp. joint infection using flucon-
azole as a sole agent has been reported in a single human 
[36]. In human medicine, amphotericin B may have poor 
absorption after oral administration and is painful when 
injected IM, potentially nephrotoxic and can exacerbate 
liver failure. For this reason we chosen fluconazole as 
treatment of the localized fungal infection. Dosage rec-
ommendations vary from 2.5 to 10 mg/kg every 12–24 h 
for treatment of candidiasis in humans. In this case flu-
conazole was dosed at 5 mg/kg once a day, which resulted 
in an effective response [22]. Even in neonatal foals flu-
conazole (4–5 mg/kg PO) has been used to treat systemic 
candidiasis and a lower toxicity than amphotericin B was 
shown [5].
A variety of treatments are available for septic arthritis, 
but long-term osteoarthritis is inevitable. The treatment 
options range from systemic drugs, local and regional 
medications, joint lavage via large bore needles, and 
arthroscopic lavage, to open arthrotomies for continu-
ous drainage [7, 37]. Although joint lavage has not been 
found to be effective in slowing the rate of progression of 
osteoarthritis without sepsis, it is recommended in sep-
tic arthritis to remove some of the inflammatory media-
tors and debris [37]. Large portals allow the removal of 
purulent debris and the use of a large volume of fluid. 
Repeated lavage or continuous drainage of the joint may 
Page 6 of 7Bufalari et al. Acta Vet Scand  (2016) 58:47 
be indicated if clinical signs persist from continued syno-
vitis or production of purulent debris [37]. The decision 
for choosing the intra-articular route for fluconazole 
administration was based on the aim to obtain a high 
concentration of compound in the joint and eliminate 
the infection more rapidly. This may be debated since in 
humans a parenteral administration of fluconazole pro-
duces substantial synovial fluid levels [38]. In this case we 
did not observe joint swelling or localized pain nor any 
other side effects in the following days after administra-
tion. As reported in horses [4] intra-articular adminis-
tration of fluconazole can be actuated without local/
systemic complications. Candida spp. joint infections 
need treatment in all cases. Since Candida spp. are less 
potent infectious agents in a healthy immunocompetent 
patient, the presence of Candida spp. infection often 
indicates a status of immune deficiency. A combined 
approach for treatment of the Candida infection and of 
the pathology responsible for immunocompromised is 
necessary.
Conclusions
To the authors’ knowledge, this is the first documented 
case of C. guilliermondii joint infection in a dog. The 
objective of this study was to document the successful 
diagnosis and treatment of fungal infectious arthritis. 
Since this is the first report on Candida spp. joint infec-
tion in a dog, no guidelines regarding treatment exist 
and the decision to administer fluconazole into the joint 
was made mainly on reports in horses. Fungal arthritis 
should be considered when encountered by joint infec-
tions, particularly in cases with a concomitant immuno-
suppression. In fact, the diagnosis of septic arthritis with 
a normally commensal fungal organism should alert the 
clinician to the possibility of local and/or systemic immu-
nocompromised state. Treatment including repeated 
joint lavage and administration of systemic and local 
(intra-articular) fluconazole resulted in eradication of the 
C. guilliermondii infection in this case.
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